Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption?
Authors:
- 1 May 2015
- journal article
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 18, 74-79
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Prognostic Parameters For Remission Of and Survival In Acquired Hemophilia A: Results Of The GTH-AH 01/2010 Multicenter StudyBlood, 2013
- Long term outcome of patients with acquired haemophilia – A monocentre interim analysis of 82 patientsAtherosclerosis Supplements, 2013
- Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)Blood, 2012
- Immunoadsorption in the treatment of Acquired HaemophiliaAtherosclerosis Supplements, 2009
- EPIDEMIOLOGY AND ONE-YEAR OUTCOMES IN PATIENTS WITH ACQUIRED HEMOPHILIA A (AH) IN FRANCE: THE SACHA PROSPECTIVE STUDYJournal of Thrombosis and Haemostasis, 2007
- Treatment of acquired haemophilia with recombinant activated FVII: a critical appraisalHaemophilia, 2007
- Treatment of acquired hemophilia by the Bonn-Malmö Protocol: documentation of an in vivo immunomodulating conceptBlood, 2005
- Acquired Haemophilia: Review and Meta‐Analysis Focused on Therapy and Prognostic FactorsBritish Journal of Haematology, 2003
- A Detailed Comparison of the Performance of the Standard versus the Nijmegen Modification of the Bethesda Assay in Detecting Factor VIII:C Inhibitors in the Haemophilia A Population of CanadaThrombosis and Haemostasis, 1998
- Acquired Factor‐IX Inhibitor in a Nonhaemophilic Patient with Autoimmune Disease*British Journal of Haematology, 1974